196 related articles for article (PubMed ID: 33588445)
21. Progression of Rebound-Associated Vertebral Fractures Following Denosumab Discontinuation Despite Reinstitution of Treatment: Suppressing Increased Bone Turnover May Not Be Enough.
Anastasilakis AD; Trovas G; Balanika A; Polyzos SA; Makras P; Tournis S
J Clin Densitom; 2021; 24(2):338-340. PubMed ID: 33218880
[TBL] [Abstract][Full Text] [Related]
22. The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies.
Kendler DL; Chines A; Brandi ML; Papapoulos S; Lewiecki EM; Reginster JY; Muñoz Torres M; Wang A; Bone HG
Osteoporos Int; 2019 Jan; 30(1):71-78. PubMed ID: 30244369
[TBL] [Abstract][Full Text] [Related]
23. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
[TBL] [Abstract][Full Text] [Related]
24. Denosumab and alendronate treatment in patients with back pain due to fresh osteoporotic vertebral fractures.
Tetsunaga T; Tetsunaga T; Nishida K; Tanaka M; Sugimoto Y; Takigawa T; Takei Y; Ozaki T
J Orthop Sci; 2017 Mar; 22(2):230-236. PubMed ID: 28087216
[TBL] [Abstract][Full Text] [Related]
25. Suboptimal medication adherence may favor the progression of vertebral fractures in women with post-menopausal osteoporosis treated with denosumab.
Betella N; Biamonte E; Matarazzo C; Piccini S; Olivetti R; Cellini M; Lania AG; Mazziotti G
Minerva Endocrinol; 2020 Sep; 45(3):165-171. PubMed ID: 32186164
[TBL] [Abstract][Full Text] [Related]
26. Stopping Denosumab.
Lamy O; Stoll D; Aubry-Rozier B; Rodriguez EG
Curr Osteoporos Rep; 2019 Feb; 17(1):8-15. PubMed ID: 30659428
[TBL] [Abstract][Full Text] [Related]
27. Treatment of high fracture risk patients in routine clinical practice.
Lesnyak O; Gladkova E; Aleksandrov N; Belaya Z; Belova K; Bezlyudnaya N; Dobrovolskaya O; Dreval A; Ershova O; Grebennikova T; Kryukova I; Mazurenko S; Priymak D; Rozhinskaya L; Samigullina R; Solodovnikov A; Toroptsova N
Arch Osteoporos; 2020 Nov; 15(1):184. PubMed ID: 33219455
[TBL] [Abstract][Full Text] [Related]
28. Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment.
Anastasilakis AD; Yavropoulou MP; Makras P; Sakellariou GT; Papadopoulou F; Gerou S; Papapoulos SE
Eur J Endocrinol; 2017 Jun; 176(6):677-683. PubMed ID: 28283537
[TBL] [Abstract][Full Text] [Related]
29. Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis.
McClung MR; Boonen S; Törring O; Roux C; Rizzoli R; Bone HG; Benhamou CL; Lems WF; Minisola S; Halse J; Hoeck HC; Eastell R; Wang A; Siddhanti S; Cummings SR
J Bone Miner Res; 2012 Jan; 27(1):211-8. PubMed ID: 21976367
[TBL] [Abstract][Full Text] [Related]
30. Multiple Rebound-Associated Vertebral Fractures after Denosumab Discontinuation: Is Prompt Antiresorptive Therapy Always Recommended,Even When the Risk of Fracture Seems Low? A Case Report.
Osella G; Puglisi S; Alì A; Reimondo G; Terzolo M
Endocr Metab Immune Disord Drug Targets; 2021; 21(12):2303-2306. PubMed ID: 34238202
[TBL] [Abstract][Full Text] [Related]
31. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.
Papapoulos S; Lippuner K; Roux C; Lin CJ; Kendler DL; Lewiecki EM; Brandi ML; Czerwiński E; Franek E; Lakatos P; Mautalen C; Minisola S; Reginster JY; Jensen S; Daizadeh NS; Wang A; Gavin M; Libanati C; Wagman RB; Bone HG
Osteoporos Int; 2015 Dec; 26(12):2773-83. PubMed ID: 26202488
[TBL] [Abstract][Full Text] [Related]
32. Risk factors for vertebral fractures and bone loss after denosumab discontinuation: A real-world observational study.
Everts-Graber J; Reichenbach S; Gahl B; Ziswiler HR; Studer U; Lehmann T
Bone; 2021 Mar; 144():115830. PubMed ID: 33359006
[TBL] [Abstract][Full Text] [Related]
33. [Multiple vertebral fractures after denosumab discontinuation].
Tjelum L; Eiken P
Ugeskr Laeger; 2018 Nov; 180(45):. PubMed ID: 30404716
[TBL] [Abstract][Full Text] [Related]
34. Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS.
Tsourdi E; Langdahl B; Cohen-Solal M; Aubry-Rozier B; Eriksen EF; Guañabens N; Obermayer-Pietsch B; Ralston SH; Eastell R; Zillikens MC
Bone; 2017 Dec; 105():11-17. PubMed ID: 28789921
[TBL] [Abstract][Full Text] [Related]
35. Teriparatide and denosumab treatment for pregnancy and lactation-associated osteoporosis with multiple vertebral fractures: A case study.
Ijuin A; Yoshikata H; Asano R; Tsuburai T; Kikuchi R; Sakakibara H
Taiwan J Obstet Gynecol; 2017 Dec; 56(6):863-866. PubMed ID: 29241936
[TBL] [Abstract][Full Text] [Related]
36. Multiple severe vertebral fractures during the 3-month period following a missed dose of denosumab in a postmenopausal woman with osteoporosis previously treated with alendronate
.
Bandeira F; Torres G; Bandeira E; Duarte MB; Nóbrega AM; Bandeira L
Int J Clin Pharmacol Ther; 2019 Mar; 57(3):163-166. PubMed ID: 30663978
[TBL] [Abstract][Full Text] [Related]
37. Magnetic resonance imaging has an advantage over conventional spine X-rays in the evaluation of rebound-associated vertebral fractures following denosumab discontinuation.
Anastasilakis AD; Evangelatos G; Makras P; Iliopoulos A
Endocrine; 2020 Sep; 69(3):516-518. PubMed ID: 32441026
[TBL] [Abstract][Full Text] [Related]
38. Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial.
Brown JP; Roux C; Törring O; Ho PR; Beck Jensen JE; Gilchrist N; Recknor C; Austin M; Wang A; Grauer A; Wagman RB
J Bone Miner Res; 2013 Apr; 28(4):746-52. PubMed ID: 23109251
[TBL] [Abstract][Full Text] [Related]
39. Denosumab utilization among older adults in Ontario: patient characteristics, persistence with therapy, and return to therapy after an extended gap.
Ban JK; Hao BB; McCarthy L; Guilcher SJT; Cadarette SM
Osteoporos Int; 2019 Sep; 30(9):1865-1872. PubMed ID: 31317248
[TBL] [Abstract][Full Text] [Related]
40. Observations following discontinuation of long-term denosumab therapy.
McClung MR; Wagman RB; Miller PD; Wang A; Lewiecki EM
Osteoporos Int; 2017 May; 28(5):1723-1732. PubMed ID: 28144701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
